Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 4/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7230355 | 0.90 | LMNA (0.39) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9097578 | 0.88 | MAP2K1 (0.37) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9096358 | 0.86 | MAP2K2 (0.38) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL7228568 | 0.84 | ALDH1A1 (0.45) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9094359 | 0.84 | ALDH1A1 (0.55) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9786233 | 0.84 | LMNA (0.46) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL8942417 | 0.84 | LMNA (0.39) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL8942028 | 0.84 | LMNA (0.59) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9534484 | 0.84 | LMNA (0.31) | LMNACYP2C9ATP6V1B2TBXA2REDNRA | |
| SCHEMBL9786221 | 0.83 | ALDH1A1 (0.47) | LMNACYP2C9ATP6V1B2TBXA2REDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0379413-B1 | 1,8-Benzonaphthyridine derivatives, their production and compositions containing them | BELLON LABOR SA ROGER (FR) | 1993-12-22 | — | — | EP | claimed |
| US-4990515-A | Chemical intermediates | RHONE-POULENC SANTE (FR) | 1991-02-05 | — | — | US | claimed |
| EP-1140932-B1 | 1,8-BENZONAPHTHYRIDINE DERIVATIVES | AVENTIS PHARMA SA (FR) | 2004-03-17 | — | — | EP | disclosed |
| US-6548506-B2 | 1-substituted,3-carboxy,7-fluoro,8-disubstituted amino-1,4-dihydrobenzo(b)(1,8)naphthyridin-4-ones; Useful as antimicrobial agents; topical antibiotic for wounds | AVENTIS PHARMA S.A. (FR) | 2003-04-15 | — | — | US | disclosed |
| US-20020037891-A1 | Novel benzo[1,8]naphthyridine derivatives, their preparation and pharmaceutical compositions which comprise them | AVENTIS PHARMA S.A. (FR) | 2002-03-28 | — | — | US | disclosed |
| EP-1140932-A1 | 1,8-BENZONAPHTHYRIDINE DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037467-A1 | 1,8-BENZONAPHTHYRIDINE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2000-06-29 | — | — | WO | disclosed |
| US-5556861-A | 1,8 benzonaphthyridine derivatives and antimicrobial compositions | LABORATOIRE ROGER BELLON (FR) | 1996-09-17 | — | — | US | disclosed |
| US-5053509-A | Microbiocides; AIDS | LABORATOIRE ROGER BELLON (FR) | 1991-10-01 | — | — | US | disclosed |
| US-4990515-A | Chemical intermediates | RHONE-POULENC SANTE (FR) | 1991-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037891-A1 | Novel benzo[1,8]naphthyridine derivatives, their preparation and pharmaceutical compositions which comprise them | ABCB11, NDUFA9, NDUFC1 | LMNA 1363/4885CYP2C9 111/4885ATP6V1B2 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.